Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug

• Published in: Molecular therapy 2020-08, Vol.28 (8), p.1759-1771
• Main Authors: Debacker, Alexandre J., Voutila, Jon, Catley, Matthew, Blakey, David, Habib, Nagy
• Format: Article
• Language: English
• Subjects: Review
• ISSN: 1525-0016; 1525-0024
• DOI: 10.1016/j.ymthe.2020.06.015

Targeted delivery of oligonucleotides to liver hepatocytes using N-acetylgalactosamine (GalNAc) conjugates that bind to the asialoglycoprotein receptor has become a breakthrough approach in the therapeutic oligonucleotide field. This technology has led to the approval of givosiran for the treatment of acute hepatic porphyria, and there are another seven conjugates in registrational review or phase 3 trials and at least another 21 conjugates at earlier stages of clinical development. This review highlights some of the recent chemical and preclinical advances in this space, leading to a large number of clinical candidates against a diverse range of targets in liver hepatocytes. The review focuses on the use of this delivery system for small interfering RNAs (siRNAs) and antisense molecules that cause downregulation of target mRNA and protein. A number of other approaches such as anti-microRNAs and small activating RNAs are starting to exploit the technology, broadening the potential of this approach for therapeutic oligonucleotide intervention. [Display omitted] Targeted delivery of oligonucleotides to hepatocytes using GalNAc conjugates has become a breakthrough approach in the therapeutic oligonucleotide field. Debacker et al. highlight recent chemical and preclinical advances in this space, leading to a large number of clinical candidates against a diverse range of targets in liver hepatocytes.